Konduru Nagarjun, Keller Jana, Ma-Hock Lan, Gröters Sibylle, Landsiedel Robert, Donaghey Thomas C, Brain Joseph D, Wohlleben Wendel, Molina Ramon M
Department of Environmental Health, Molecular and Integrative Physiological Sciences Program, Harvard School of Public Health, 665 Huntington Avenue, Boston, MA, 02115, USA.
Experimental Toxicology and Ecology, BASF SE, GV/TB - Z470, Carl-Bosch-Straße 38, Ludwigshafen, 67056, Germany.
Part Fibre Toxicol. 2014 Oct 21;11:55. doi: 10.1186/s12989-014-0055-3.
Nanoparticulate barium sulfate has potential novel applications and wide use in the polymer and paint industries. A short-term inhalation study on barium sulfate nanoparticles (BaSO₄ NPs) was previously published [Part Fibre Toxicol 11:16, 2014]. We performed comprehensive biokinetic studies of ¹³¹BaSO₄ NPs administered via different routes and of acute and subchronic pulmonary responses to instilled or inhaled BaSO₄ in rats.
We compared the tissue distribution of ¹³¹Ba over 28 days after intratracheal (IT) instillation, and over 7 days after gavage and intravenous (IV) injection of ¹³¹BaSO₄. Rats were exposed to 50 mg/m³ BaSO₄ aerosol for 4 or 13 weeks (6 h/day, 5 consecutive days/week), and then gross and histopathologic, blood and bronchoalveolar lavage (BAL) fluid analyses were performed. BAL fluid from instilled rats was also analyzed.
Inhaled BaSO₄ NPs showed no toxicity after 4-week exposure, but a slight neutrophil increase in BAL after 13-week exposure was observed. Lung burden of inhaled BaSO₄ NPs after 4-week exposure (0.84 ± 0.18 mg/lung) decreased by 95% over 34 days. Instilled BaSO₄ NPs caused dose-dependent inflammatory responses in the lungs. Instilled BaSO₄ NPs (0.28 mg/lung) was cleared with a half-life of ≈ 9.6 days. Translocated ¹³¹Ba from the lungs was predominantly found in the bone (29%). Only 0.15% of gavaged dose was detected in all organs at 7 days. IV-injected ¹³¹BaSO₄ NPs were predominantly localized in the liver, spleen, lungs and bone at 2 hours, but redistributed from the liver to bone over time. Fecal excretion was the dominant elimination pathway for all three routes of exposure.
Pulmonary exposure to instilled BaSO₄ NPs caused dose-dependent lung injury and inflammation. Four-week and 13-week inhalation exposures to a high concentration (50 mg/m³) of BaSO₄ NPs elicited minimal pulmonary response and no systemic effects. Instilled and inhaled BaSO₄ NPs were cleared quickly yet resulted in higher tissue retention than when ingested. Particle dissolution is a likely mechanism. Injected BaSO₄ NPs localized in the reticuloendothelial organs and redistributed to the bone over time. BaSO₄ NP exhibited lower toxicity and biopersistence in the lungs compared to other poorly soluble NPs such as CeO₂ and TiO₂.
纳米硫酸钡在聚合物和涂料行业具有潜在的新应用和广泛用途。此前已发表了一项关于硫酸钡纳米颗粒(BaSO₄ NPs)的短期吸入研究[《颗粒与纤维毒理学》11:16,2014年]。我们对经不同途径给予的¹³¹BaSO₄ NPs进行了全面的生物动力学研究,并对大鼠经气管内滴注或吸入BaSO₄后的急性和亚慢性肺部反应进行了研究。
我们比较了气管内(IT)滴注¹³¹BaSO₄后28天内以及经口灌胃和静脉内(IV)注射¹³¹BaSO₄后7天内¹³¹Ba在组织中的分布。将大鼠暴露于50 mg/m³的BaSO₄气溶胶中4周或13周(每天6小时,每周连续5天),然后进行大体和组织病理学、血液及支气管肺泡灌洗(BAL)液分析。还对经滴注的大鼠的BAL液进行了分析。
暴露于BaSO₄ NPs 4周后未显示出毒性,但在暴露13周后观察到BAL中中性粒细胞略有增加。暴露于BaSO₄ NPs 4周后(0.84±0.18 mg/肺),肺部负担在34天内下降了95%。经气管内滴注的BaSO₄ NPs在肺部引起了剂量依赖性炎症反应。经气管内滴注的BaSO₄ NPs(0.28 mg/肺)以约9.6天的半衰期清除。从肺部转移的¹³¹Ba主要存在于骨骼中(29%)。在7天时,在所有器官中仅检测到0.15%的经口灌胃剂量。静脉注射¹³¹BaSO₄ NPs在2小时时主要定位于肝脏、脾脏、肺和骨骼,但随着时间的推移从肝脏重新分布到骨骼。粪便排泄是所有三种暴露途径的主要消除途径。
肺部暴露于经气管内滴注的BaSO₄ NPs会导致剂量依赖性肺损伤和炎症。暴露于高浓度(50 mg/m³)的BaSO₄ NPs 4周和13周后,引起的肺部反应最小且无全身影响。经气管内滴注和吸入的BaSO₄ NPs清除迅速,但与摄入时相比,组织滞留量更高。颗粒溶解可能是一种机制。注射的BaSO₄ NPs定位于网状内皮器官,并随着时间的推移重新分布到骨骼。与其他难溶性纳米颗粒如CeO₂和TiO₂相比,BaSO₄ NPs在肺部表现出较低的毒性和生物持久性。